Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  De Zeeuw, D ^a   Remuzzi, G ^b   Kirch, W ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Candesartan cilexetil; Hepatic impairment; Pharmacokinetics; Renal impairment

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030723207     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[[2′(1H-tetrazol- 5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993, 266: 114-120.
2. Elmfeldt D, George M, Hübner R, Olofsson B, Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
3. Belcher G et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S85-S89.
4. 14C-candesartan cilexetil in healthy volunteers, J Hum Hypertens 1997; 11 (Suppl 2): S27-S28.
5. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. 1997; J Hum Hypertens 11 (Suppl 2): S19-S25.
6. Buter H, Nevis G, de Zeeuw D, de Jong PE. Renal hemodynamic effects of candesartan in normal and impaired renal function in man. Kidney Int 1997; (Suppl): (in press).
7. th Meeting American Society of Hypertension, San Francisco, CA: 28-31 May 1997 (abstract).